GDTC files 6-K on cash bid for TC BioPharm’s assets

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reported that it has submitted a cash bid of an undisclosed sum for a potential acquisition of selected, potentially synergistic assets of TC BioPharm Limited. The announcement was made on October 14, 2025, and notes that TC BioPharm entered administration on October 2, 2025.

The update signals an interest in expanding CytoMed’s capabilities through asset acquisition, though terms and valuation were not disclosed. A related press release is furnished as Exhibit 99.1. As this is a bid for assets rather than a completed transaction, outcomes and financial effects depend on subsequent developments and any negotiated terms.

Insights

Biotech transactions analyst

CytoMed filed a cash bid for TCBL assets; details undisclosed.

CytoMed Therapeutics submitted a cash bid to acquire potentially synergistic assets from TC BioPharm, which entered administration on October 2, 2025. Asset purchases from administration can focus on IP, programs, or equipment, typically without assuming broader liabilities, but the excerpt does not specify scope.

Without a disclosed price or asset list, financial impact cannot be gauged. The move indicates strategic interest rather than a completed deal, and any effect would hinge on accepted terms and closing mechanics.

The press release dated October 14, 2025 is furnished as Exhibit 99.1. Further company disclosures would be needed to understand which assets are included and the cash consideration.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 14, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing it has submitted a cash bid of an undisclosed sum in relation to a potential acquisition of potentially synergistic assets of TC BioPharm Limited (“ TCBL”), which entered administration on October 2, 2025.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Press Release dated October 14, 2025, titled: “CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets”

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: October 14, 2025	Title:	Director and Chairman

FAQ

What did GDTC announce in the Form 6-K?

CytoMed Therapeutics announced it submitted a cash bid of an undisclosed sum to potentially acquire selected assets of TC BioPharm Limited.

Why is TC BioPharm Limited relevant to GDTC’s announcement?

TC BioPharm entered administration on October 2, 2025, and CytoMed bid on potentially synergistic assets made available through that process.

Is the CytoMed acquisition of TCBL assets completed?

No. The update states CytoMed submitted a cash bid for a potential acquisition; it does not report a completed transaction.

Did CytoMed disclose the bid amount or specific assets?

No. The announcement refers to an undisclosed sum and describes the assets as potentially synergistic without listing specifics.

Where can I find more details from CytoMed?

A press release dated October 14, 2025 is furnished as Exhibit 99.1 with the Form 6-K.